Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2012 2
2019 1
2020 1030
2021 1172
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

2,032 results
Results by year
Filters applied: . Clear all
Page 1
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Wang Y, et al. Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Lancet. 2020. PMID: 32423584 Free PMC article. Clinical Trial.
Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 123 [95% CI 087-175]). ...Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped
Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 123 [95% CI 087-175]). ...Adverse e
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ, Kebriaei R, Dresser LD. Jorgensen SCJ, et al. Pharmacotherapy. 2020 Jul;40(7):659-671. doi: 10.1002/phar.2429. Epub 2020 Jun 28. Pharmacotherapy. 2020. PMID: 32446287 Free PMC article. Review.
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being eval …
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has …
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Spinner CD, et al. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. JAMA. 2020. PMID: 32821939 Free PMC article. Clinical Trial.
Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group. ...By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and …
Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Singh AK, Singh A, Singh R, Misra A. Singh AK, et al. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):641-648. doi: 10.1016/j.dsx.2020.05.018. Epub 2020 May 12. Diabetes Metab Syndr. 2020. PMID: 32428865 Free PMC article. Review.
BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe C …
BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In …
Treatment options for COVID-19: The reality and challenges.
Jean SS, Lee PI, Hsueh PR. Jean SS, et al. J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4. J Microbiol Immunol Infect. 2020. PMID: 32307245 Free PMC article. Review.
Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependen …
Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in …
Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Malin JJ, et al. Clin Microbiol Rev. 2020 Oct 14;34(1):e00162-20. doi: 10.1128/CMR.00162-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33055231 Free PMC article. Review.
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first approved treatment for severe coronavirus disease 20 …
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress …
Antiviral treatment of COVID-19.
Şimşek Yavuz S, Ünal S. Şimşek Yavuz S, et al. Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145. Turk J Med Sci. 2020. PMID: 32293834 Free PMC article. Review.
The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been …
The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipi …
Remdesivir and COVID-19.
Wang LY, Cui JJ, Ouyang QY, Zhan Y, Guo CX, Yin JY. Wang LY, et al. Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5. Lancet. 2020. PMID: 33010833 Free PMC article. No abstract available.
Emerging treatment strategies for COVID-19 infection.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30. Clin Exp Med. 2021. PMID: 33128197 Free PMC article. Review.
Possible treatment and strategies for COVID-19: review and assessment.
Trivedi N, Verma A, Kumar D. Trivedi N, et al. Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057. Eur Rev Med Pharmacol Sci. 2020. PMID: 33336780 Free article. Review.
Based on the evidence, hydroxychloroquine is the first medicine opted for the treatment of disease. Umifenovir, remdesivir, and fevipiravir are deemed the most hopeful antiviral agent by improving the health of infected patients. ...
Based on the evidence, hydroxychloroquine is the first medicine opted for the treatment of disease. Umifenovir, remdesivir, and fevip …
2,032 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page